The doses will be delivered through the end of January 2021 with at least 350,000 doses being delivered in December 2020. Bamlanivimab received for emergency use authorization for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.

The purchase brings the total doses purchased by the U.S. government to 950,000. According to the government, Americans will have no out-of-pocket costs for the medicine. The federal government is responsible for allocation of the drug, with weekly allocation decisions made based on confirmed COVID-19 cases in each state and territory over the previous seven days.

FDA issues EUA for Lilly's JAK inhibitor plus remdesivir for COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the drug baricitinib, a janus kinase (JAK) inhibitor,...

Lilly partners with Samsung Biologics to manufacture COVID-19 antibodies
Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.

FDA grants Lilly EUA for its COVID-19 mAb
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Eli Lilly's investigational monoclonal antibody (mAb) therapy,...

Eli Lilly to supply U.S. with 300,000 doses of anti-SARS-CoV-2 antibody
Eli Lilly has entered an initial agreement with the U.S. government to supply 300,000 vials of LY-CoV555 (bamlanivimab), the company's investigational...